

# PRIOR AUTHORIZATION CRITERIA

**BRAND NAME**  
(generic)

**XEPI**  
(ozenoxacin)

**Status: CVS Caremark Criteria**

**Type: Initial Prior Authorization with Quantity Limit**

## POLICY

### FDA-APPROVED INDICATIONS

Xepi is indicated for the topical treatment of impetigo due to *Staphylococcus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age and older.

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the topical treatment of impetigo due to *Staphylococcus aureus* or *Streptococcus pyogenes* in a patient 2 months of age or older

**AND**

- The patient has experienced an inadequate treatment response to a trial of topical mupirocin

**OR**

- The patient has experienced an intolerance to topical mupirocin

**OR**

- The patient has a contraindication that would prohibit a trial of topical mupirocin

**AND**

- The requested drug is not being used in a footbath

Quantity Limits apply.

30 grams per 25 days\*

*\*This drug is for short-term acute use; therefore, the mail limit will be the same as retail limit. The intent is for prescriptions of the requested drug to be filled one month at a time, even if filled at mail order; there should be no 3-month supplies filled.*

### REFERENCES

1. Xepi [package insert]. Woburn, MA: Biofrontera Inc.; January 2020.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2022; Accessed September 9, 2022.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed September 9, 2022.
4. Stevens DL, Bisno AL, Chambers HF, et al: Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2014;59(2):e10-e52.
5. Hartman-Adams H, Banvard C, Juckett G. Impetigo: Diagnosis and Treatment. *Am Fam Physician*. 2014;90(4):229-235.
6. Eichenfield L, Tom W, Berger T, et al. Guidelines of Care for the Management of Atopic Dermatitis Section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. *J Am Acad Dermatol*. 2014;71:116-32.
7. U.S. Department of Health & Human Services. Burn Triage and Treatment – Thermal Injuries. Chemical Hazards Emergency Medical Management. August 16, 2021. Available at: <https://chemm.hhs.gov/burns.htm>. Accessed September 2, 2022.